Cited by 605CAR-T cell therapy researchCancer Immunotherapy and BiomarkersOccupational and environmental lung diseases

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Open access

Adusumilli, Prasad S., Zauderer, Marjorie G., Rivière, Isabelle, Solomon, Stephen B., Rusch, Valerie W., O'Cearbhaill, Roisin E., Zhu, Amy, Cheema, Waseem, Chintala, Navin K., Halton, Elizabeth, Pineda, John, Perez-Johnston, Rocio, Tan, Kay See, Daly, Bobby, Araujo Filho, Jose A., Ngai, Daniel, McGee, Erin, Vincent, Alain, Diamonte, Claudia, Sauter, Jennifer L., Modi, Shanu, Sikder, Devanjan, Senechal, Brigitte, Wang, Xiuyan, Travis, William D., Gönen, Mithat, Rudin, Charles M., Brentjens, Renier J., Jones, David R., Sadelain, Michel·2021·Cancer Discovery

DOI 10.1158/2159-8290.cd-21-0407PMC PMC8563385

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response. We developed and conducted a first-in-human, phase I study of regionally delivered, autologous, mesothelin-targeted chimeric antigen receptor (CAR) T-cell therapy. Intrapleural administration of 0.3M to 60M CAR T cells/kg in 27 patients (25 with MPM) was safe and well tolerated. CAR T cells were detected in peripheral blood for >100 days in 39% of patients. Following our demonstration that PD-1 blockade enhances CAR T-cell function in mice, 18 patients with MPM also received pembrolizumab safely. Among those patients, median overall survival from CAR T-cell infusion was 23.9 months (1-year overall survival, 83%). Stable disease was sustained for ≥6 months in 8 patients; 2 exhibited complete metabolic response on PET scan. Combination immunotherapy with CAR T cells and PD-1 blockade agents should be further evaluated in patients with solid tumors. Significance: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is feasible, safe, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors. See related commentary by Aldea et al., p. 2674. This article is highlighted in the In This Issue feature, p. 2659

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-21-0407

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Self-citation
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial
Baas, P., Scherpereel, A., Nowak, A. K., Fujimoto, N., Peters, S., Tsao, A. S., Mansfield, A. S., Popat, S., Jahan, T., Antonia, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32714-8 · Cited by 1,215
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,098
Self-citation
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J. F., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,062
Self-citation
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial
Zalcman, G., Mazieres, J., Margery, J., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Molinier, O., Corre, R., Monnet, I., Gounant, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01238-6 · Cited by 968
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Self-citation
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
Self-citation

Show all 37 references

Sorted by citations

Items 201–300 of 599

Precision sniper for solid tumors: CAR-NK cell therapy
Li, S., Jing, J., Chen, Y., Chi, E., Wang, B., Xie, Z., Yang, W., Shen, H., & Pan, J. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04106-z · Cited by 19
Current state of CAR-T cell therapies for solid tumors
Rosa, R. C. A., Liu, J., Lu, C., Abou‐El‐Enein, M., Murad, J. P., & Priceman, S. J. (2026) · Med · doi:10.1016/j.medj.2026.101028 · Cited by 21
Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors
Kimura, Y., Ghosn, M., Cheema, W., Adusumilli, P. S., Solomon, S. B., & Srimathveeralli, G. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.018 · Cited by 18
Self-citation
Germline T cell receptor exchange results in physiological T cell development and function
Rollins, M. R., Raynor, J. F., Miller, E. A., Butler, J. Z., Spartz, E. J., Lahr, W. S., You, Y., Burrack, A. L., Moriarity, B. S., Webber, B. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36180-1 · Cited by 18
CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours
Tang, H., Wang, B., Tan, H.-X., Sarwar, M., Baraka, B., Shafiq, T., & Rao, A. (2023) · Cells · doi:10.3390/cells12121586 · Cited by 15
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Cesano, A., Augustin, R. C., Barrea, L., Bedognetti, D., Bruno, T. C., Carturan, A., Hammer, C., Ho, W. S., Kather, J. N., Kirchhoff, T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008876 · Cited by 20
Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review
Ma, P., Jiang, Y., Zhao, G., Wang, W., Xing, S., Tang, Q., Miao, H., Fang, H., Chao, S., Yuan, F., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114224 · Cited by 17
Redefining the Diagnostic and Therapeutic Landscape of Non-Small Cell Lung Cancer in the Era of Precision Medicine
Khan, S., Upadhyay, S., Kauser, S., Hasan, G. M., Lu, W., Waters, M., Hassan, M. I., & Sohal, S. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228021 · Cited by 18
Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment
Antoñana-Vildosola, A., Zanetti, S. R., & Palazón, A. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.004 · Cited by 17
Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions
Dalal, P., Patel, N. P., Feinstein, M. J., & Akhter, N. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221132927 · Cited by 17
The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy
Orama, S. B., & Sheth, R. A. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-8 · Cited by 17
Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
Yang, Z., & Wang, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002549 · Cited by 18
Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential
Chamorro, D. F., Somes, L. K., & Hoyos, V. (2023) · Cancers · doi:10.3390/cancers16010124 · Cited by 20
Leveraging the pleural space for anticancer therapies in pleural mesothelioma
Blyth, K. G., Adusumilli, P. S., Astoul, P. J., Darlison, L., Lee, G., Mansfield, A. S., Marciniak, S. J., Maskell, N. A., Panou, V., Peikert, T., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00111-5 · Cited by 17
Self-citation
Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): a multicentre, open-label, randomised, phase 2/3 study
Aerts, J. G. J. V., Belderbos, R. A., Baas, P., Scherpereel, A., Bezemer, K., Enninga, I. C., Meijer, R. R., Willemsen, M., Berardi, R., Fennell, D. A., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00191-8 · Cited by 17
Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment
Chen, Q., Sun, Y., & Li, H. (2024) · Discover Oncology · doi:10.1007/s12672-024-01159-x · Cited by 17
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Sun, Y., Maggs, L., Panda, A., Wright, S. J., Cicerchia, A. M., Jenney, A., Perricone, M. D., Mills, C. E., Cattaneo, G., Ventin, M., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-1011 · Cited by 17
Self-citation
PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models
Lesch, S., Nottebrock, A., Rataj, F., Heise, C., Endres, S., & Kobold, S. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00747-9 · Cited by 17
Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8 + T cells eradicates peritoneal metastases in mouse models
Trani, C. A. D., Cirella, A., Arrizabalaga, L., Bella, Á., Fernández-Sendin, M., Russo-Cabrera, J. S., Gomar, C., Olivera, I., Bolaños, E., González-Gomariz, J., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2147317 · Cited by 17
Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
Gemelli, M., Cortinovis, D. L., Baggi, A., di Mauro, P., Calza, S., Berruti, A., Grisanti, S., & Rota, M. (2022) · Cancers · doi:10.3390/cancers14246063 · Cited by 17
Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions
Ruan, L., & Wang, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1530541 · Cited by 16
Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
Davies, J. S., Karimipour, F., Zhang, L., Nagarsheth, N., Norberg, S. M., Serna, C., Strauss, J., Chiou, S., Gulley, J. L., & Hinrichs, C. S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004906 · Cited by 18
Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions
Pal, K., & Sheth, R. A. (2022) · Cancers · doi:10.3390/cancers15010196 · Cited by 16
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives
Maher, J. F. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s341179 · Cited by 16
Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate
Sun, Z., Chu, X., Adams, C., Ilina, T. V., Guerrero, M., Lin, G., Chen, C., Jelev, D. V., Ishima, R., Li, W., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.09.002 · Cited by 16
The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future Directions
Bertin, B., Zugman, M., & Schvartsman, G. (2023) · Cancers · doi:10.3390/cancers15245808 · Cited by 17
Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms
Wang, Y., Bergman, D. R., Trujillo, E., Pearson, A. T., Sweis, R. F., & Jackson, T. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-49467-6 · Cited by 16
Development of Personalized Strategies for Precisely Battling Malignant Melanoma
Isaak, A. J., Clements, G. R., Buenaventura, R. G. M., Merlino, G. T., & Yu, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25095023 · Cited by 17
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
Dreyzin, A., Rankin, A. W., Luciani, K., Gavrilova, T., & Shah, N. N. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2349738 · Cited by 17
Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions
Ligon, J. A., Wessel, K. M., Shah, N. N., & Glod, J. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.846346 · Cited by 16
Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review)
Rijavec, E., Biello, F., Barletta, G., Dellepiane, C., & Genova, C. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2522 · Cited by 16
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
Wala, J. A., & Hanna, G. J. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.009 · Cited by 16
A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation
Meng, Y., Sun, J. Y., & Zhang, G. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104403 · Cited by 16
Emerging drug targets for colon cancer: A preclinical assessment
Crutcher, M. M., Baybutt, T. R., Kopenhaver, J. S., Snook, A. E., & Waldman, S. A. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2039119 · Cited by 15
Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications
Li, Y., Jiang, H., Luo, L., & Mei, H. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06482-z · Cited by 14
Lipid nanoparticles for engineering next generation CAR T cell immunotherapy
Ang, M. J. Y., Metzloff, A. E., Thatte, A. S., & Mitchell, M. J. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00432b · Cited by 14
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
Choo, J. R.-E., Sargsyan, A., Khachatryan, V., Lonardi, S., Pietrantonio, F., Sundar, R., Klempner, S. J., & Janjigian, Y. Y. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01134-1 · Cited by 17
Immunotherapy in malignant peritoneal mesothelioma (Review)
Alaklabi, S., Roy, A. M., Skitzki, J. J., & Iyer, R. V. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2627 · Cited by 14
The Landscape of Adoptive Cellular Therapies in Ovarian Cancer
Davis, L., Miller, R. E., & Wong, Y. N. S. (2023) · Cancers · doi:10.3390/cancers15194814 · Cited by 14
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
Calabrò, L., Bronte, G., Grosso, F., Cerbone, L., Delmonte, A., Nicolini, F., Mazza, M., Giacomo, A. M. D., Covre, A., Lofiego, M. F., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1333661 · Cited by 14
Candidate tumor-specific CD8 + T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis
Sugita, Y., Muraoka, D., Demachi‐Okamura, A., Komuro, H., Masago, K., Sasaki, E., Fukushima, Y., Matsui, T., Shinohara, S., Takahashi, Y., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2371556 · Cited by 14
Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
Li, L., Pu, H., Zhang, X., Guo, X., Li, G., & Zhang, M. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104683 · Cited by 16
Current Management and Future Perspective in Pleural Mesothelioma
Shah, R., Klotz, L. V., & Glade, J. (2022) · Cancers · doi:10.3390/cancers14041044 · Cited by 14
High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma
Chu, G. J., Linton, A., Kao, S., Klebe, S., Adelstein, S., Yeo, D., Rasko, J. E. J., & Cooper, W. A. (2023) · Histopathology · doi:10.1111/his.14916 · Cited by 14
In-depth analysis of the safety of CAR-T cell therapy for solid tumors
Dong, J., Wu, J., Ye, J., Zhu, Z., Su, T., Shao, L., Bei, J., & Chen, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548979 · Cited by 13
Platinum‐Based Chemotherapeutics in the Modern Era: From Classical DNA ‐Targeting Mechanisms to Next‐Generation Innovations in Cancer Therapy
Shahsavani, M. B., Heidari, M., Yousefi, R., & Moosavi‐Movahedi, A. A. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70208 · Cited by 13
Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy
Zhang, Z., Cui, D., Wang, H., Wu, L., & Liu, X. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04278-8 · Cited by 13
CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead
Shaer, N. S. H. A., Masoud, I., Tleyjeh, A., Al-Attas, A. A., Al-Attas, M. A., Khan, M. I., & Yaqinuddin, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1796675 · Cited by 15
Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors
Liu, S., & Zhang, Y. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.03.03 · Cited by 13
Lymphodepletion in Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: A Focus on Brain Tumors
Ju, A., Choi, S., Jeon, Y., & Kim, K. (2024) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2024.0037 · Cited by 13
Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies
Sherpally, D., & Manne, A. (2025) · Cancers · doi:10.3390/cancers17040589 · Cited by 13
Challenges in the preclinical design and assessment of CAR-T cells
Tomai, R. A., Rivas, J. D. L., Fetică, B., Bergantim, R., Filipić, B., Gagić, Ž., Nikolic, K. M., Gulei, D., Kegyes, D., Nistor, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1564998 · Cited by 14
Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma
Zhang, Y., Geng, H., Zeng, L., Li, J., Yang, Q., Jia, S., Zong, X., Cai, W., Liu, S., Lu, Y., et al. (2023) · Hematological Oncology · doi:10.1002/hon.3227 · Cited by 13
Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors
Guo, J., Zhou, C., Zhao, H., & Li, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1652329 · Cited by 12
The new era of prostate-specific membrane antigen-directed immunotherapies and beyond in advanced prostate cancer: a review
Martin, F. C., Dorff, T. B., & Tran, B. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231170474 · Cited by 12
A Bispecific Antibody That Targets the Membrane-Proximal Region of Mesothelin and Retains High Anticancer Activity in the Presence of Shed Mesothelin
Chakraborty, A., Onda, M., O’Shea, T., Wei, J., Liu, X., Bera, T. K., & Pastan, I. H. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0233 · Cited by 12
Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors
Wachholz, G. E., Akbari, P., Huijbers, E. J. M., Jalan, P., B, J. R. V. B., & Griffioen, A. W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189155 · Cited by 12
CAR-T cell technologies that interact with the tumour microenvironment in solid tumours
Taylor, C. A., Glover, M., & Maher, J. F. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2380894 · Cited by 12
CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant
Ikeda, S., Hasegawa, K., Kogue, Y., Arimori, T., Kawamoto, R., Wibowo, T., Yaga, M., Inada, Y., Uehara, H., Matsubara, M., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00934-1 · Cited by 12
Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment
Fowler, D. W., Nattress, C. B., Southern, A., Barisa, M., & Fisher, J. P. H. (2021) · Cancers · doi:10.3390/cancers13236000 · Cited by 12
Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors
Conejo-Garcia, J. R., & Guevara-Patino, J. A. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2096463 · Cited by 12
Time to abandon CAR-T monotherapy for solid tumors
Yin, L., Wan, Z., Sun, P., Shuai, P., & Liu, Y. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188930 · Cited by 12
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
Giraudo, L., Cattaneo, G., Gammaitoni, L., Iaia, I., Donini, C., Massa, A., Centomo, M. L., Basiricò, M., Vigna, E., Pisacane, A. M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02884-x · Cited by 12
Intraperitoneal CAR T-cell therapy for peritoneal carcinomatosis from gastroesophageal cancer: preclinical investigations to a phase I clinical trial (NCT06623396)
Restle, D. J., Amador-Molina, A., Misawa, K., Banerjee, S., Ku, G. Y., & Adusumilli, P. S. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012292 · Cited by 11
Self-citation
Inhibitory receptor CD47 binding to plasma TSP1 suppresses NK-cell IFN-γ production via activating the JAK/STAT3 pathway during HIV infection
Lang, B., Wang, M., Zhang, Z., Fu, Y., Han, X., Hu, Q., Ding, H., Shang, H., & Jiang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04667-6 · Cited by 11
A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect
Bai, Y., Yang, X., Chen, K.-T., Cuan, X.-D., Zhang, Y., Zhou, L., Yang, L., Liu, H., & Yuan, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116759 · Cited by 11
The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
Banerji, S. O., Meyers, D. E., Harlos, C. H., & Dawe, D. E. (2021) · Current Oncology · doi:10.3390/curroncol28060385 · Cited by 11
Treatment of Patients with Malignant Peritoneal Mesothelioma
Li, C. Y., Kennedy, T. J., & Alexander, H. R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071891 · Cited by 11
Research advances of nanoparticles for CAR-T therapy in solid tumors
Chen, B., Gong, L., Feng, J. Q., Jin, M., Chen, L., Gao, Z., & Huang, W. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109432 · Cited by 10
Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies
Liu, Y., Cao, P., Ahad, F., Zaidi, S. A. A., Muluh, T. A., & Fu, Q. (2024) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928277331231218115402 · Cited by 10
PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors
Chen, X., Zhao, X., Mou, X., Zhao, J., Zhang, Z., Zhang, X., Huang, J., Liu, Y., Wang, F., Zhang, M., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116800 · Cited by 10
CAR T-cells for pediatric solid tumors: where to go from here?
Trautmann, T., Yakobian, N., & Nguyen, R. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10214-6 · Cited by 10
BRD4 inhibitor reduces exhaustion and blocks terminal differentiation in CAR-T cells by modulating BATF and EGR1
Sui, S., Zhong, M., Zhong, S., Peng, X., Mao, L., Chen, C., Zeng, C., Luo, O. J., & Li, Y. (2024) · Biomarker Research · doi:10.1186/s40364-024-00667-w · Cited by 12
Daidzein Inhibits Non-small Cell Lung Cancer Growth by Pyroptosis
Zeng, F., Zhang, Y., Luo, T., Wang, C., Fu, D., & Wang, X. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128330530240918073721 · Cited by 10
Self-citation
Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
Nelson, B. E., Naing, A., Fu, S., Sheth, R. A., Murthy, R., & Piha-Paul, S. A. (2024) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2024.101040 · Cited by 10
Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma
Kato, T., Tanaka, I., Huang, H., Okado, S., Imamura, Y., Nomata, Y., Takenaka, H., Watanabe, H., Kawasumi, Y., Nakanishi, K., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094299 · Cited by 10
Systemic delivery of cadherin 17–specific CAR T cells allows effective and safe targeting of colorectal cancer liver metastases
Greco, B., Khoury, R. E., Balestrieri, C., Sirini, C., Machado, A., Girardi, F. D., Rossi, L., Botrugno, O. A., Giovannoni, G., Falcone, L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adr1928 · Cited by 13
Adoptive cell therapy for cancer: combination strategies and biomarkers
Liu, S., Jiang, W., Sheng, J., Wang, L., & Cui, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603792 · Cited by 10
CAR T-cell immunotherapy as the next horizon in cancer eradication: current landscape, challenges, and future directions
Bharadia, H., Dabhade, A., Shah, A. C., Patel, R., Chorawala, M. R., Patel, A., & Shah, P. A. (2025) · Medical Oncology · doi:10.1007/s12032-025-02957-1 · Cited by 11
New advances in pharmaceutical strategies for sensitizing anti‐PD ‐1 immunotherapy and clinical research
Jiang, M., Qin, B., Li, X., Liu, Y., Guan, G., & You, J. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1837 · Cited by 10
Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies
Liu, Q., Liu, Z., Wan, R., & Huang, W. (2022) · Cancers · doi:10.3390/cancers14184452 · Cited by 10
CAR T-cell behavior and function revealed by real-time imaging
Espie, D., & Donnadieu, E. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-023-00983-7 · Cited by 11
Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer
Zhu, Y., Zuo, D., Wang, X., Lan, S., He, H., Chen, L., Chen, X., & Feng, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05279-9 · Cited by 10
Self-citation
CAR T cells in solid tumors and metastasis: paving the way forward
Sirini, C., Rossi, L., Moresco, M. A., & Casucci, M. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10213-7 · Cited by 10
Unravelling the modified T cell receptor through Gen-Next CAR T cell therapy in Glioblastoma: Current status and future challenges
Bhutani, B., Sharma, V., Ganguly, N. K., & Rana, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117987 · Cited by 9
Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?
Simula, L., Ollivier, E., Icard, P., & Donnadieu, E. (2022) · Cells · doi:10.3390/cells11111854 · Cited by 10
The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma
Borgeaud, M., Kim, F., Friedlaender, A., Lococo, F., Addeo, A., & Minervini, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051757 · Cited by 10
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity
Chu, G. J., Bailey, C. G., Nagarajah, R., Liang, O., Metierre, C., Sagnella, S. M., Castelletti, L., Yeo, D., Adelstein, S., & Rasko, J. E. J. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.01.011 · Cited by 9
CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy
Yaga, M., Hasegawa, K., Ikeda, S., Matsubara, M., Hiroshima, T., Kimura, T., Shirai, Y., Wibowo, T., Uehara, H., Tachikawa, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-68779-9 · Cited by 9
Cellular Therapies for Multiple Myeloma: Engineering Hope
Vera-Cruz, S., Culubret, M., Konetzki, V., Alb, M., Friedel, S. R., Hudecek, M., Einsele, H., Danhof, S., & Scheller, L. (2024) · Cancers · doi:10.3390/cancers16223867 · Cited by 9
From Bench to Bedside: Emerging Paradigms in CAR‐T Cell Therapy for Solid Malignancies
Chen, Y., Ren, R., Yan, L., Zhou, Y., Sun, R., Song, H., Yan, H., & Li, Y. (2025) · Advanced Science · doi:10.1002/advs.202505822 · Cited by 9
CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management
Liu, Y., Gao, Y., Huo, C., Zeng, T., Meng, W., Zhang, H., & He, Q. (2026) · Translational Oncology · doi:10.1016/j.tranon.2025.102662 · Cited by 9
Overcoming functional and translational challenges of cellular immunotherapies for solid tumors
Chen, Y.-C., Chen, K., Levine, B. L., & Shah, K. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.02.002 · Cited by 9
Chimeric antigen receptor T cells therapy in solid tumors
Rababah, F., Alabduh, T., Awawdeh, A., Shatnawi, T., AL-shdaifat, M., Ibdah, E., Shatnawi, S., AbuZetun, Y. I., Helaly, A. M., & Ghorab, D. S. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03122-8 · Cited by 9
Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy
Desai, A. P., Kosari, F., Disselhorst, M., Yin, J., Agahi, A., Peikert, T., Udell, J. B. M., Johnson, S. H., Smadbeck, J. B., Murphy, S. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006035 · Cited by 9
Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma
Teppert, K., Winter, N., Herbel, V., Brandes, C., Lennartz, S., Engert, F., Kaiser, A., Schaser, T., & Lock, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1178060 · Cited by 9
Regional and intratumoral adoptive T-cell therapy
Olivera, I., Etxeberría, I., Luri‐Rey, C., Molero-Glez, P., & Melero, I. (2024) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2024.100715 · Cited by 9
Remodeling the hepatic immune microenvironment and demolishing T cell traps to enhance immunotherapy efficacy in liver metastasis
Luo, Z., Jiang, M., Cheng, N., Zhao, X., Liu, H., Wang, S., Lin, Q., Huang, J., Guo, X., Liu, X., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.057 · Cited by 9
Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy
Xu, F., Ni, Q., Gong, N., Xia, B., Zhang, J., Guo, W., Hu, Z., Li, J., & Liang, X. (2024) · Advanced Materials · doi:10.1002/adma.202407525 · Cited by 11
Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas
Mir, S. A., Venugopalan, A. K., Zhang, J., Nair, N. U., Sengupta, M., Khanal, M., Stathopoulou, C., Jiang, Q., & Hassan, R. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70057 · Cited by 9

Authors: Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., Pineda, J., Perez-Johnston, R., Tan, K. S., Daly, B., Araujo Filho, J. A., Ngai, D., McGee, E., Vincent, A., Diamonte, C., Sauter, J. L., Modi, S., Sikder, D., Senechal, B., Wang, X., Travis, W. D., Gönen, M., Rudin, C. M., Brentjens, R. J., Jones, D. R., & Sadelain, M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
6Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
5Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Corresponding author: Adusumilli, Prasad S.
ORCID: Adusumilli, Prasad S.
Zauderer, Marjorie G.
Rivière, Isabelle
Solomon, Stephen B.
Rusch, Valerie W.
O'Cearbhaill, Roisin E.
Cheema, Waseem
Chintala, Navin K.
Pineda, John
Perez-Johnston, Rocio
Tan, Kay See
Daly, Bobby
Sauter, Jennifer L.
Modi, Shanu
Wang, Xiuyan
Travis, William D.
Gönen, Mithat
Rudin, Charles M.
Brentjens, Renier J.
Jones, David R.
Sadelain, Michel
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2021-07-15
Volume: 11
Issue: 11
Pages: 2748-2763
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-21-0407
PMC: PMC8563385
OpenAlex: W3179214161
Cited by: 605
References: 37
Citations by year: 2026: 124 · 2025: 119 · 2024: 131 · 2023: 125 · 2022: 90 · 2021: 15
FWCI: 32.88
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: NIH (P30 CA008748, R01 CA236615-01, R01 CA235667)
U.S. Department of Defense (BC132124, LC160212, CA180889)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords: mesothelin, chimeric antigen receptor T cells, CAR T-cell therapy, malignant pleural mesothelioma, malignant pleural effusion, pembrolizumab, anti-PD-1 therapy, intrapleural administration, combination immunotherapy, autologous T cells, safety and tolerability, overall survival
MeSH terms: Mesothelin, Humans, Mesothelioma, Pleural Diseases, Immunotherapy, Adoptive, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks